Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Acquires Additional Securities of Resverlogix Corp.
Calgary, Alberta--(Newsfile Corp. - May 21, 2021) - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") announces that on May 13, 2021, it acquired 10% secured convertible debentures due May 13, 2022, of Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF) (the "Company") in the principal amount of US$6 million and 300,000 common share purchase warrants of the Company by way of a private placement (the "Private Placement") for a purchase price of US$6 million (Cdn$7.4 million). The...
2021-05-21 5:10 PM EDT